Avalyn Pharma (NASDAQ:AVLN) Trading Up 6.5% Following Analyst Upgrade

Avalyn Pharma Inc. (NASDAQ:AVLN)’s share price was up 6.5% during trading on Thursday after Zacks Research upgraded the stock to a hold rating. The stock traded as high as $28.59 and last traded at $28.57. Approximately 8,663 shares changed hands during trading, a decline of 97% from the average daily volume of 345,549 shares. The stock had previously closed at $26.82.

Several other brokerages have also commented on AVLN. Jefferies Financial Group started coverage on Avalyn Pharma in a research report on Monday. They set a “buy” rating and a $52.00 price objective on the stock. Guggenheim started coverage on Avalyn Pharma in a research report on Monday. They set a “buy” rating and a $80.00 price target on the stock. Morgan Stanley started coverage on Avalyn Pharma in a research report on Tuesday. They set an “overweight” rating and a $53.00 price target on the stock. Wall Street Zen upgraded Avalyn Pharma to a “hold” rating in a research report on Saturday, May 9th. Finally, Evercore started coverage on Avalyn Pharma in a research report on Tuesday. They set an “outperform” rating and a $51.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Avalyn Pharma has a consensus rating of “Buy” and a consensus price target of $59.00.

Insider Buying and Selling

In other Avalyn Pharma news, Director Jill Carroll acquired 277,778 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $5,000,004.00. Following the transaction, the director owned 2,186,562 shares in the company, valued at $39,358,116. This represents a 14.55% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was acquired at an average price of $18.00 per share, for a total transaction of $9,999,990.00. Following the completion of the transaction, the insider owned 2,186,562 shares in the company, valued at approximately $39,358,116. The trade was a 34.06% increase in their position. The SEC filing for this purchase provides additional information.

Avalyn Pharma Stock Performance

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.